Unproven stem cell-based interventions & harm to existing & future patients

Published: 27 March 2022
Editorial
Flora Naylor,
Kirstin RW Matthews




“To address these risks to current and future patients, companies developing SCBIs should work with policymakers and patient advocates to protect clinical research and the reputation of the field.”

Read now